The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key…
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses…
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases…
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),…
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch…
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment…
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company…
Global Hemp Food Leader, Manitoba Harvest, Launches New Superseed Instant Oatmeal in Three Delicious Flavors Packed with Plant-Based Protein, Fiber,…
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of…